Dueling Democrat, Republican ACA subsidy plans fail in Senate
fiercehealthcare - Dueling partisan proposals to address the expiry of the Affordable Care Act subsidies both failed to advance in the Senate on Thursday.
AI Summary: In a pivotal Senate showdown, dueling bipartisan proposals to extend ACA subsidies collapsed, leaving millions at risk of higher premiums. Lawmakers’ partisan clashes underscored deep divides in healthcare policy and uncertainty over future insurance affordability.
Tanning beds mutate skin cells far beyond the reach of ordinary sunlight, study shows
medicalxpress - Tanning bed use is tied to almost a three-fold increase in melanoma risk, and for the first time, scientists have shown how these devices cause melanoma-linked DNA damage across nearly the entire skin surface, reports a new study led by Northwestern Medic…
AI Summary: A groundbreaking study reveals that tanning beds cause widespread DNA damage in skin cells – nearly tripling melanoma risk compared to sunlight exposure. The research provides the first definitive evidence that these artificial light sources trigger mutations at levels comparable to a “three‐fold” increase, raising serious public health concerns.
Texas sues Epic over alleged EHR monopoly
Emily Olsen / healthcaredive - The suit also accuses Epic of restricting parents’ access to children’s medical records. Epic called the complaint “flawed and misguided.”
AI Summary: Texas Attorney General Ken Paxton has filed a lawsuit against Epic Systems alleging that the company monopolizes the electronic health records market and restricts parental access to children’s medical records—a move that has sparked regulatory and legal scrutiny over its alleged anti‐competitive practices.
AHA President Rick Pollack to retire by end of 2026
fiercehealthcare - Longtime American Hospital Association President Rick Pollack will retire by the end of 2026, the organization announced on Wednesday.
AI Summary: Longtime American Hospital Association President Rick Pollack is set to retire by the end of 2026, signaling a major leadership transition in U.S. hospital lobbying. Reports note his decades‐long influence and spark speculation about the AHA’s next era of strategic direction.
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial
Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…
AI Summary: An international Phase III trial led by UCLA reveals that giredestrant, a novel endocrine therapy, significantly reduces recurrence risk in early‐stage breast cancer compared with standard care. The robust findings promise to shift hormonal treatment paradigms—even if skeptics may raise a wry eyebrow at yet “another” incremental advance in a crowded field.
ACA approval hits new high as subsidies set to expire: 7 things to know
Alan Condon / beckershospitalreview - Approval of the ACA recently climbed to a new high of 57% — driven largely by a surge in support among independents — even as pandemic‑era enhanced subsidies are set to expire Dec. 31 unless Congress acts, according to a survey published Dec. 8 by the Wes…
AI Summary: Multiple reports point to growing concerns that the impending expiration of expanded Affordable Care Act subsidies could leave millions facing steep premium hikes or loss of coverage. Survey findings and policy analyses underscore the potential financial strain on vulnerable populations as the deadline nears.
A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
go - A new study suggests a single HPV vaccination appears just as effective as two doses at preventing the viral infection that causes cervical cancer
AI Summary: A new study finds that a single dose of the HPV vaccine offers comparable protection against cervical cancer as the traditional two‐dose regimen, potentially simplifying vaccine delivery and increasing immunization rates in public health initiatives.
CVS Health agrees to pay $37.8M to settle fraud allegations over insulin pens
fiercehealthcare - CVS Health agreed to pay $37.76 million to settle allegations that it dispensed too many insulin pens to patients and improperly billed federal healthcare programs for those prescriptions.
AI Summary: CVS Health has agreed to pay approximately $38 million to settle allegations that it improperly dispensed insulin pens and misbilled federal health programs, resolving accusations of fraudulent practices and restoring trust in its operations.
Will All Newborns Still Receive Hepatitis B Shots? A Committee’s Vote Will Tell.
Apoorva Mandavilli / nytimes - The federal vaccine panel appointed by Health Secretary Robert F. Kennedy Jr. is likely to decide on Thursday that the shots should be delayed for infants whose mothers test negative for the virus.
AI Summary: Multiple posts detail a contentious re‐evaluation of the newborn hepatitis B vaccination schedule. As a federal committee prepares for a key vote, figures such as RFK Jr. warn that delaying routine vaccination may leave infants less protected, sparking heated debate across the healthcare community.
California Discourages Wild Mushroom Foraging After Fatal Outbreak
Hannah Ziegler / nytimes - Officials said one person was killed and 20 others were poisoned after eating death cap mushrooms, which look and taste like safe mushrooms but can cause liver failure.
AI Summary: California health officials report that a deadly outbreak—killing one person and poisoning 20 others after death cap mushrooms were mistaken for edible varieties—has forced officials to warn the public against wild mushroom foraging. The state identified 21 poisoning cases, leaving foragers with a grim reminder to stick to their grocery store mushrooms.
Startup Protego Bio Lands $130M for First-in-Class Drug’s Pivotal Test in Rare Plasma Disorder
Frank Vinluan / medcitynews - Protego Biopharma’s lead program is a potential treatment for the rare disease light chain amyloidosis. The startup says the novel mechanism of its oral small molecule should have better outcomes than antibodies from AstraZeneca and Prothena that failed t…
AI Summary: Two reports reveal that Protego Bio has raised $130M to fund pivotal clinical testing of its novel therapy for AL amyloidosis, a rare plasma disorder. This funding milestone, backed by industry leaders, marks a significant advance in treatment options for a challenging condition.
Volcanic eruptions may have brought Black Death to Europe
medicalxpress - Previously unknown volcanic eruptions may have kicked off an unlikely series of events that brought the Black Death—the most devastating pandemic in human history—to the shores of medieval Europe, new research has revealed.
AI Summary: New research is challenging old assumptions about the Black Death by linking a series of volcanic eruptions to climate shifts that may have facilitated the pandemic’s spread. The studies suggest that these explosive natural events triggered environmental changes with far‐reaching public health consequences in medieval Europe.
ACIP drops universal hepatitis B birth dose recommendation
Max Bayer / endpoints - A panel of CDC vaccine advisors has stopped recommending that all children receive the hepatitis B vaccine at birth, overruling scientific consensus and public health officials who pleaded that there was no grounded rationale for ...
AI Summary: A panel of CDC vaccine advisors has upended decades‑old practice by halting the universal administration of hepatitis B vaccine at birth. Citing evolving scientific evidence, the change aims to more precisely target high‑risk infants and re‐calibrate newborn immunization protocols, representing a significant policy pivot in pediatric healthcare.
A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes
fiercehealthcare - Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from 12 former commissioners of the agency.
AI Summary: A dozen former FDA commissioners have fiercely criticized the proposed overhaul of U.S. vaccine regulations spearheaded by FDA official Vinay Prasad, warning it could undermine decades‐old safety standards and erode public trust in immunization.
FDA approves all ages gene therapy for spinal condition
Ella Jeffries / beckershospitalreview - The FDA approved Novartis’ Itvisma (onasemnogene abeparvovec-brve), the company’s first and only gene replacement therapy for spinal muscular atrophy in children 2 and older, as well as for teens and adults. The therapy is designed to address the genetic …
AI Summary: The FDA has given the green light to Novartis’ gene replacement therapy Itvisma for the treatment of spinal muscular atrophy, a development that extends its use to patients of all ages. The approval, which responds to long‐standing concerns over safety and patient eligibility, marks a significant milestone in SMA care.
Novo submits high-dose Wegovy for FDA approval using voucher
Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...
AI Summary: Novo Nordisk has formally submitted its application to the FDA to approve a higher-dose formulation of its flagship obesity drug, Wegovy. Leveraging a recently secured priority voucher, the filing is set to potentially expand treatment options for weight management as the review process begins.
CASSANDRA-PACT-21 Trial Update: Preoperative PAXG vs mFOLFIRINOX in Resectable and Borderline Resectable PDAC
oncodaily - The landscape of early-stage pancreatic ductal adenocarcinoma (PDAC) continues to evolve as clinicians move from surgery-first strategies toward perioperative treatment. Neoadjuvant and perioperative approaches have shown growing promise, yet no […]
AI Summary: New findings from the CASSANDRA study indicate that a neoadjuvant quadruplet PAXG regimen significantly improves event‐free survival versus traditional mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, suggesting a potential shift in treatment guidelines.
Tracking with care: The ethics of using location tracking technology with people living with dementia
medicalxpress - Imagine you're 83 years old, living with dementia in a long-term care home. Lately, your caregivers keep asking you to wear a bracelet on your wrist 24/7. They say it's for your safety, so they can locate you quickly when needed.
AI Summary: As care providers turn to real‐time tracking devices for people with dementia, questions of privacy versus safety now dominate the debate. Critics contend that constant monitoring can undermine personal autonomy, while proponents emphasize its potential to prevent emergencies. The discussion highlights the ethical balance between protection and individual dignity.
Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials
Ella Jeffries / beckershospitalreview - Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo…
AI Summary: Novo Nordisk’s much‑talked‑about GLP‑1 drug, famed for its weight‐loss benefits, has hit an unexpected wall in Alzheimer’s trials. In two separate reports – one on the standard injectable and another on a pill form – semaglutide showed no statistically significant impact on slowing brain decline. Who knew obesity meds couldn’t multitask?
FDA Approves Pembrolizumab + Enfortumab Vedotin-ejfv for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
oncodaily - What Does FDA Approval Mean? The U.S. Food and Drug Administration (FDA) evaluates new cancer therapies to determine whether they are safe and effective for clinical use. Approval is based […]
AI Summary: The U.S. Food and Drug Administration has approved a combination of pembrolizumab (Keytruda) and enfortumab vedotin (Padcev) for patients with muscle‐invasive bladder cancer who cannot tolerate cisplatin. Both agents—which have individually transformed treatment paradigms—are now linked in a perioperative setting that could alter outcomes for this aggressive cancer.